Adis Newsletters
Accesskeys
- [Alt + 0] - Homepage
- [Alt + 1] - to the top
- [Alt + 5] - Search Form
- [Alt + 6] - Sitemap
- [Alt + 7] - to within-page navigation
- [Alt + 8] - to content
- [Alt + 9] - Contact Form
Global Servicelinks
Navigation
content
Detailed Information: Adis Newsletters (AN83)
Adis Newsletters is a full text bibliographical database on the most important development about drugs and drug therapy. The database contains bibliographical data, keywords describing the content, full texts and references. It complies to the three journals (subunits) as regards contents:
- Reactions (pharmacovigilance, studies and reports of adverse drug reactions)
- Inpharma (current news from the area of drugs and drug therapy)
- PharmacoEconomics & Outcomes News (economic aspects of drug therapy)
Content navigation
- Database Content: Subject Coverage | Type | Language | Sources | Superbases
- Database Resources: File Size | File Data | Update Cycle
- Query: Special Notes | Vocabulary | Searchable Data Fields | Data Fields, alphabetical | Output of Search Results | Sample Search(es) | Sample Record(s)
- Contact: Producer | Contact Person
- Appendix: Appendix
Database Content
| Subject Coverage | Drugs and drug therapy |
|---|---|
| Type | Full text database |
| Language | English |
| Sources |
|
| Superbases | There are predefined databases groups (superbase) for several subjects. The database Adis Newsletters is part of the following superbases: |
Database Resources
| File Size | 124,519 (Status 06/2012) |
|---|---|
| File Data |
Reactions: 1983 to present Growth per year: approx. 4,600 documents You will find the number of database records in the current update status. |
| Update Cycle | Daily |
Query
Special Notes
A search in the field "Document Type (DT)" runs both via the Document Type of the document as well as that of the associated references.
The database is searchable both with DIMDI SmartSearch and DIMDI ClassicSearch.
No authors are indicated for the full texts. However, the authors of the references are searchable (RA= Referenced Author).
Individual full texts are published identically (partly with modified title) in the different journals (identifiable by the same NDAN numbers). Possibly found duplicates can be eliminated to a large extent before the output of the target information with the command "ch dup" to avoid unnecessary costs.
The use of presently 30 qualifiers in connection with the Controlled Terms (CT), (e.g. clobetasol/therapeutic use) is possible. By their use the context can be described in detail.
Standing orders (SDI) are possible for Premium customers.
Vocabulary
Controlled Term (CT)
Language of vocabulary: English
Searchable Data Fields
The following documents sections are considered with the free text search (FT):
Controlled Term (CT)
Document Type (DT)
Referenced Document Type (RDT)
Referenced Title (RTI)
Text (TEXT)
Title (TI)
Search language(s) in the basic index:
English
Data Fields, alphabetical
Explanation:
D = DISPLAY F = FIND S = SHOW
1 : front-end-masking recommended
2 : searchable word by word with field label
3 : searchable only selectively
(F): field is searchable only via basic index
| Command | Field Name | Examples | Notes |
|---|---|---|---|
| D F S | CT Controlled Term | F CT=anaphylaxis | Keywords (describing the contents) which are further specifiable with qualifiers (see below). |
| F | /QF = xx Qualifier | F CT=ibuprofen/QF=adverse reactions | Combination with qualifiers. |
| D F S | DT Document Type | F ... AND DT=case report D DT=? |
|
| D F S | ISSN ISSN | F ISSN=01149954 | International Standard Serial Number; part of ND. |
| D F S | JT Journal Title | F JT=inpharma | Equals: SU Subunit; part of the field Source (SO); there are only 3 journals: Reactions, Inpharma, PharmacoEconomics & Outcomes News. |
| D F S | ND Number of Document | F ND=an01149954-800973018 | Composed of NDAN and ISSN. |
| D F S | NDAN Number of Document in Adis Newsletters | F NDAN=800973018 | Part of ND. |
| D F S | PD Publication Date | F PD=19830114 | Part of SO. Format: YYYYMMDD. |
| D F S | PY Publication Year | F ... AND PY>=1998 | |
| D F S | QF Qualifier | D QF=? F QF=pharmacodynamics |
Alphabetical list of all qualifiers. Qualifiers are searchable individually or in combination with Controlled Terms (CT) (see field CT). |
| D F S | RA Referenced Author | F RA=lehmann a | Part of RF. |
| D F S | RCY Referenced Country | F RCY=germany D RCY=? |
Part of RF. |
| D F S | RDT Referenced Document Type | F RDT=media release D RDT=? |
Part of RF. |
| D 1 F 1 S | RF References | F RF=?adverse drug reaction? | Composed of RA, RTI, RJ, RY, RPD, RCY, RLA, RDT. |
| D F S | RJ Referenced Journal | F RJ=acta neurologica? | Part of RF. |
| D F S | RLA Referenced Language | F ... AND RLA=germ D RLA=? |
Part of RF. |
| D F S | RN Number of References | F RN=5 | Number of references underlying the document. |
| D F S | RPD Referenced Publication Date | F RPD=19800201 | |
| (F) S | RTI Referenced Title | F FT=ibuprofen?/RTI | Title of the original source; part of the field RF. |
| D F S | RY Referenced Year | F RY=1990 | Year of publication of the reference source; part of the field RF. |
| S | SO Source | Composed JT und PD. | |
| D F S | SU Subunit | F SU=inpharma | Equals: JT Journal Title (see above). |
| (F) S | TEXT Text | F FT=ibuprofen?/TEXT | |
| ( F) S | TI Title | F FT=ibuprofen?/TI |
Output of Search Results
By means of the commands: SHOW (S) / MAIL / SDI.
Corresponding to the copyright rules use the parameter USE=DLOAD if necessary.
You may ask for all data fields, single data fields, or sets of data fields. If the output fields are not specified explicitly, the standard field set (F=STD) is used in all output commands.
Output field sets:
| Command | Field Set | Associated Datafields |
|---|---|---|
| F=STD | standard | same as F=ALL |
| F=ALL | all fields | ND (incl. NDAN), TI, SO (incl. JT, PD), ISSN, DT, RN, CT, TEXT, RF (incl. RA, RTI, RJ, RY, RPD, RCY, RLA, RDT) |
| F=SO | source | JT, PD |
| F=DES | descriptors | CT |
Sample Search(es)
Selecting base in DIMDI ClassicSearch: SBAS AN83
Subject:
Articles that are particularly concerned with the side effects of the use of Paracetamol on children.
Profile table:
| Parameter | Counter | Number of Hits | Query |
|---|---|---|---|
| C= | 1 | 63048 | AN83 |
| S= | 2 | 3626 | CT=CHILDREN |
| 3 | 127 | CT=PARACETAMOL/QF=ADVERSE REACTIONS | |
| 4 | 5 | 2 AND 4 |
Sample Record(s)
2/1 of 606 DIMDI: Adis Newsletters (AN83) © Wolters Kluwer Health - Adis International
| ND: | AN01562703-800888635 |
| TI: | Product news: US market news. |
| SO: | Inpharma /20021108/ |
| ISSN: | 01562703 |
| DT: | Text and citations |
| RN: | 10 |
| CT: | AE 941 Neovastat/therapeutic use; Clobetasol/therapeutic use; Clozapine/therapeutic use; Doxercalciferol/therapeutic use; Emtricitabine/therapeutic use; Oxycodone/ ibuprofen/therapeutic use; Pravastatin/therapeutic use; Product approvals; Regulatory process; Secretin/therapeutic use; Testosterone/therapeutic use |
| TEXT: |
Bentley Pharmaceuticals' topical gel formulation of testosterone [`Testim'] has been approved by the US FDA for the treatment of men with hypogonadism.(1) A supplemental new drug application (NDA) for secretin [`SecreFlo'; Repligen] has been approved by the FDA, allowing the product to be used in a new indication, for use as an aid in the location and cannulation of the pancreatic ducts in patients undergoing endoscopic retrograde cholangiopancreatography.(2) The product is already approved for use in stimulation of pancreatic secretions to aid in the diagnosis of pancreatic exocrine dysfunction or chronic pancreatitis and stimulation of gastrin secretion to aid in the diagnosis of gastrinoma. A new indication has been approved by the FDA for pravastatin [`Pravachol'; Bristol-Myers Squibb].(3) The product may now be used in the treatment of paediatric patients aged >= 8 years with heterozygous familial hypercholesterolaemia. Triangle Pharmaceuticals' new drug application for the nucleoside reverse transcriptase inhibitor emtricitabine [`Coviracil'] has been accepted for filing by the FDA.(4) If approved, the product will be used for the treatment of HIV infection. An FDA advisory committee has recommended the approval of a new indication for clozapine [`Clozaril'; Novartis], the treatment of emergent suicidal behaviour in patients with schizophrenia or schizoaffective disorder.(5) Bone Care International has received an approvable letter from the FDA in regard to the company's supplemental NDA concerning the use of the oral formulation of 1-alpha-hydroxyvitamin-D sub(2) [`Hectoral'] in treating secondary hyperparathyroidism in patients with chronic kidney disease prior to undergoing dialysis.(6) The FDA has issued an approvable letter to Connetics Corporation for the supplemental use of its 0.05% foam formulation of clobetasol [`Olux'], for the topical treatment of nonscalp psoriasis, reports Scrip.(7) The product is already available in the US for the treatment of scalp dermatoses. The FDA has granted orphan drug status to AEterna Laboratories' antiangiogenic agent AE 941 [`Neovastat'] for the treatment of renal cell carcinoma.(8) An approvable letter has been issued by the FDA for Forest Laboratories' combination oxycodone/ ibuprofen analgesic for the treatment of moderate- to-severe pain, but advises that approval can only be granted upon Forest conducting additional clinical trials, reports Marketletter.(9) |
| RF: | Bentley Pharmaceuticals Inc. U.S. FDA Approves Marketing of Testim Testosterone Replacement Gel; Gel Enhanced by Bentley Pharmaceuticals' CPE-215 Drug Delivery Technology; Media Release, 2002, 1 Nov 2002. Available from; 20021101; USA; English; Media release |
| US market news; Inpharma, 2002, 1363, 22; 20021109; English; News item | |
| Repligen Corporation. Repligen Announces FDA Approval of New Indication for SecreFlo(TM); Media Release, 2002, 4 Nov 2002. Available from; 20021104; USA; English; Media release | |
| Bristol-Myers Squibb Company. U.S. Food and Drug Administration Approves Pravachol (R) (Pravastatin Sodium) for Use in Pediatric Patients; Media Release, 2002, 31 Oct 2002. Available from; 20021031; USA; English; Media release | |
| Triangle Pharmaceuticals Inc. Coviracil(R) NDA for the Treatment of HIV Disease Accepted by the Food and Drug Administration; Media Release, 2002, 4 Nov 2002. Available from; 20021104; USA; English; Media release | |
| Novartis Pharmaceuticals Corporation. FDA Committee Recommends Approval for Clozaril(R) to Treat Suicidal Behavior; Media Release, 2002, 4 Nov 2002. Available from; 20021104; USA; English; Media release | |
| Bone Care International Inc. FDA Issues Approvable Letter for Hectorol Capsules in Chronic Kidney Disease Patients; Media Release, 2002, 29 Oct 2002. Available from; 20021029; USA; English; Media release | |
| 7. Connetics' Olux approvable for non-scalp psoriasis; Scrip, 2002, 24; 20021101; England; English; News item | |
| AEterna Laboratories Inc. FDA Grants Orphan-Drug Status to AEterna's Neovastat(R) for Kidney Cancer; Media Release, 2002, 29 Oct 2002. Available from; 20021029; Canada; English; Media release | |
| 9. Forest must do more trials on painkiller; Marketletter, 2002, 29, 22; 20021028; England; English; News item |
Output format: SHOW F=ALL
Contact
Producer
- WoltersKluwer Health
Pharma Solutions
Chowley Oak Lane
Tattenhall
Chester, CH3 9GA
Great Britain
Phone: +44 1829 77 11 55
Fax: +44 1829 77 03 30
Contact Person
- Database Search Drugs:
DIMDI
Phone: +49 221 4724-523
E-mail: Helpdesk Pharma - Service, Contract, Prices:
DIMDI
Phone: +49 221 4724-270
E-mail: Technical Helpdesk
Appendix
Appendix
- Copyright: DIMDI -